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Abstract
Microglia (brain resident macrophages) accumulate in malignant gliomas and instead of initiating the anti-tumor response,
they switch to a pro-invasive phenotype, support tumor growth, invasion, angiogenesis and immunosuppression by release
of cytokines/chemokines and extracellular matrix proteases. Using immunofluorescence and flow cytometry, we
demonstrate an early accumulation of activated microglia followed by accumulation of macrophages in experimental
murine EGFP-GL261 gliomas. Those cells acquire the alternative phenotype, as evidenced by evaluation of the production of
ten pro/anti-inflammatory cytokines and expression profiling of 28 genes in magnetically-sorted CD11b
+ cells from tumor
tissues. Furthermore, we show that infiltration of implanted gliomas by amoeboid, Iba1-positive cells can be reduced by a
systematically injected cyclosporine A (CsA) two or eight days after cell inoculation. The up-regulated levels of IL-10 and
GM-CSF, increased expression of genes characteristic for the alternative and pro-invasive phenotype (arg-1, mt1-mmp,
cxcl14) in glioma-derived CD11b
+ cells as well as enhanced angiogenesis and tumor growth were reduced in CsA-treated
mice. Our findings define for the first time kinetics and biochemical characteristics of glioma-infiltrating microglia/
macrophages. Inhibition of the alternative activation of tumor-infiltrating macrophages significantly reduced tumor growth.
Thus, blockade of microglia/macrophage infiltration and their pro-invasive functions could be a novel therapeutic strategy
in malignant gliomas.
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Introduction
Recent experimental and pre-clinical studies show an important
role of tumor-infiltrating macrophages in tumor growth, metastasis
and response to cancer treatments [1,2]. Tumor-associated
macrophages are attracted by tumor-released molecules which
induce reprogramming/differentiation of macrophages into anti-
inflammatory cells known as alternatively activated, in contrast to
inflammatory M1-type macrophages. M2-type macrophages from
experimental tumors and various types of cancers express
arginase-1 (Arg1), IL-10 and transforming growth factor beta 1
(TGF-b1), support tumor invasion, angiogenesis and matrix
remodelling [2,3,4]. The stromal signals influencing glioma
progression are poorly known and are likely distinct from those
implicated in non-nervous system cancers. Microglia are brain
resident macrophages, which respond to pathogens or injury in the
brain. Once activated (e.g. by lipopolysaccharide - LPS or
interferon gamma - IFNc) they are characterized by increased
chemotaxis, production of inflammation mediators and cytokines,
activation of the respiratory burst, and they become immune
effector cells mediating both innate and adaptive responses [5,6].
Histopathologic and flow cytometry studies of human glioma
tissue have shown high intratumoral microglia density which
correlates with the grade of malignancy [7,8,9]. Microglial cells in
tumors do not secrete cytokines critical in developing effective
innate immune responses and an anti-tumor immune response is
suppressed in glioma patients [9,10,11]. The presence of cells
positively stained for CD163 and CD204, putative markers for
‘‘M2’’ macrophages [12], as well as myeloid-derived suppressor
cell-like cells have been detected in glioma patients [13]. Several
glioma-secreted factors have been characterized as promoting
microglial chemotaxis: macrophage colony-stimulating factor 1
[12,14], granulocyte/macrophage colony-stimulating factor [15],
hepatocyte growth factor [16] and monocyte chemotactic protein
3 [17]. Immunosuppressive properties of glioma cancer stem cells,
producing CSF-1, TGF-b1 and macrophage inhibitory cytokine,
and inducing polarisation of recruited macrophages/microglia
have been demonstrated [18,19,20].
Experimental studies using brain organotypic slices depleted of
microglia, genetic models of microglia ablation and microglia-
glioma co-cultures pinpoint a pro-invasive role of glioma-
infiltrating microglia [21,22]. Glioma-exposed microglia release
metalloproteinase MT1-MMP which activates a latent metallo-
proteinase 2 (pro-MMP-2) produced by glioma cells that promotes
tumor invasion, as was shown using brain slices from MT1-MMP-
deficient mice and in a microglia depletion model [23].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23902Furthermore, microglial cells secrete active TGF-b1, which
stimulates glioblastoma invasion [24].
In the present study, we demonstrate that microglia and
macrophages accumulate in GL261 experimental gliomas, adapt
an anti-inflammatory ‘‘M2’’ phenotype, express arginase-1, IL-10
and MMPs. To interfere with glioma-microglia interactions, we
used cyclosporine A (CsA) which has been shown to reduce
microglia activation and invasion of glioma cells in vitro and in
organotypic brain slices [22]. Systemically-applied CsA inhibits
microglia/macrophage infiltration, induces cell death of infiltrat-
ing cells and blocks expression/activity of enzymes and cytokines,
important for the establishment of a pro-invasive phenotype of
glioma-infiltrating microglia/macrophages. This results in consid-
erable reduction of tumor growth and angiogenesis. Our results
demonstrate that counteracting infiltration of microglia/macro-
phages into tumor and their differentiation into the ‘‘M2’’
phenotype could be a novel strategy in glioma therapy.
Materials and Methods
Ethics statement
This study was conducted under the protocol 857/2008, which
was approved by the Local Ethics Committee for Animal
Experimentation at the Nencki Institute of Experimental Biology.
Cell culture and treatment
GL261-glioma cells stably expressing pEGFP-N1 [21] obtained
from Prof. Helmut Kettenmann (MDC, Berlin, Germany) were
cultured in DMEM with 10% FBS (Gibco, MD, USA) and
antibiotics (50 U/ml penicillin, 50 mg/ml streptomycin) in a
humidified atmosphere of CO2/air (5%/95%) at 37uC (Heraeus,
Hanau, Germany). Cyclosporine A (CsA) was purchased from
Novartis (Sandimmum, Switzerland) and FK506 from Astellas
(Prograf, Astellas Co. Ltd., Ireland). Drugs diluted in PBS were
added to cultured cells or intraperitoneally (i.p.) injected to tumor-
bearing mice.
Primary cultures of astrocytes were prepared from cerebral
cortex of 2-day-old C57BL/6 newborn mice as described
previously [25]. Astrocytes were cultured in DMEM with high
glucose (GlutaMAX
TM, Gibco) supplemented with 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin.
In vivo studies
Male C57BL/6 mice (12–16 wk) were anesthetized with an i.p.
injection of ketamine (75 mg/kg) and medetomidine (1 mg/kg).
EGFP-GL261 glioma cells (8610
4 cells in 1 ml of DMEM) were
inoculated in a right striatum using 1-ml syringe with a 26-gauge
needle in a stereotactic apparatus (Stoelting Co., USA), according
to the coordinates (+1.5 mm AP, 21.5 ML). Mice were
resuscitated using i.p. administration of atipamazole and an-
algezed with Tolfedine 4% (4 mg/kg s.c.; Vetoquinol).
After tumor implantation, the animals were housed individually
and randomly assigned to treatments: CsA (2 or 10 mg/kg) or
FK506 (1 mg/kg) every 2 days starting from the 2nd day after cell
implantation (early treatment); every day from 8th day after
glioma implantation (postponed treatment); control mice received
PBS injections. At day 15th after glioma implantation, the animals
were anesthetized, sacrificed and perfused with 4% paraformal-
dehyde in PBS. The brains were removed, post-fixed for 24 h in
the same fixative solution and placed in 30% sucrose in PBS at
4uC. Next, brains were frozen with dry CO2 and serial 20-mm-
thick coronal sections were collected using a cryostat. Images were
acquired using a Leica DM4000B microscope.
Quantification of tumor volume
Tumor areas in coronal sections were measured using Image
Pro-Plus software (v.6.1, Media Cybernetics, Silver Spring, MD) in
every second 40-mm brain slice and volumes were calculated
according to the Cavalieri principle using algorithm described
below.
V~0:08
X n{1
i~1
AizAn  0:04 mm3   
Legend: V – volume; Ai – tumor area in a slice; An – tumor area in
a last slice; 0.08 – constant distance between slices together with
slice thickness; 0.04 – thickness of a last slice.
Immunohistochemistry
Staining with anti-Iba1 antibody was used to detect microglia in
the tumor-bearing sections. Sections were treated with a blocking
solution (3% normal goat serum, 0.1% Triton X-100 in PBS) for
30 min at room temperature, then stained with the rabbit anti-
Iba1 antibody (1:500, Wako, Japan) overnight at 4uC, followed by
2 h incubation with the Alexa Fluor 647-conjugated goat anti-
rabbit antibody (1:500, Invitrogen).
TUNEL staining was performed on 20-mm free-floating sections
with the biggest tumor area according to the manufacturer’s
protocol (In situ Cell Detection Kit, TMR, Roche Molecular
Biochemicals, Indianapolis, IN, USA). Free-floating sections were
first incubated in 99% ethanol and 80% acetic acid (2:1 ratio) at
4uC for 30 min and then for 30 min in the blocking solution: 5%
bovine serum albumin, 3% normal goat serum in 0.1% TBS.
Subsequently, after brief washing in PBS, sections were incubated
with TUNEL reaction mixture for 1 h at 37uC in a dark humid
chamber. For the positive control, sections from a sham-operated
brain were treated with DNase I (Sigma) prior to labelling.
Negative control slices were incubated with a mixture without
enzyme. Thereafter, sections were incubated with primary
antibodies: rabbit anti-Iba1 (1:500, Wako, Japan), rabbit anti-
GFAP (1:500, DakoCytomation), rabbit anti-NSE (1:100, Chemi-
con) in the blocking solution overnight at 4uC. After washing, slices
were stained with Alexa Fluor 647-conjugated goat anti-rabbit
antibody (Invitrogen) in the blocking solution at 1:500 dilution for
2 h at 25uC. Incubation was followed by labeling with DAPI
(Sigma), dehydration in alcohol and mounting with DPX
Mountant for histology (Fluka). Brain sections were examined
under a fluorescent Leica DM4000B microscope and a confocal
microscope (TCS SP2, Leica). Image Pro-Plus software was used
for quantification of TUNEL-positive cells.
Measurement of pro- and anti-inflammatory cytokines in
brain extracts
Measurement of pro- and anti-inflammatory cytokines was
performed in whole brain extracts from naı ¨ve and tumor-bearing
mice; 2 ml of LPS (1 mg/ml, Sigma) was injected intracerebrally as
a positive control. Naı ¨ve, LPS-treated (6 h post-injection) and
tumor-bearing mice (14 d after glioma implantation) were
anesthetized and transcardially perfused with ice-cold PBS.
Ipsilateral hemispheres were quickly collected and tissues were
homogenized in 106 volume lysis buffer (50 mmol/L Tris-HCl,
pH 7.4, 150 mmol/L NaCl, 1% Nonidet P-40, 0.1% SDS), with
protease inhibitors (2 mg/ml leupeptin, 2 mg/ml aprotinin,
1 mmol/L PMSF) on ice using a homogenizer (Ultra-Turrax
T8, Ika-Werke). After centrifugation (10 000 g) for 10 min at 4uC,
the supernatants were collected and stored at 280uC. The levels of
cytokines were measured using the FlowCytomix Mouse Th1/Th2
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extracts were incubated with a mixture of antibodies-coated
fluorescent beads characterized by different size and fluorescent
signature. Next, a biotin-conjugated antibody mix followed by a
streptavidin-PE solution were added to the beads to quantify the
captured analyte. Samples were run on a flow cytometer
(FACScan, Becton Dickinson), analyzed with FlowCytomix Pro
2.2 Software (Bender MedSystems), and referred to a standard
curve. Results were expressed as pg/ml for each cytokine.
Isolation of CD11b-positive cells and flow cytometry
Naı ¨ve, sham-operated and tumor-bearing mice were anesthe-
tized and decapitated. Brains were removed, brain tissues were cut
into small pieces and single-cell suspension was achieved by
enzymatic digestion using the Neural Tissue Dissociation Kit
(Papain) from Miltenyi Biotec. The tissue was further mechanically
dissociated using a wide-tipped, fire-polished Pasteur pipette and
the suspension was applied to a 30 mm cell strainer. Cells were
processed immediately for MASC MicroBead separation. The
CD11b-positive cells were magnetically labelled with CD11b
MicroBeads. The cell suspension was loaded onto a MACS
Column (Miltenyi Biotec) placed in the magnetic field of a MACS
Separator and a negative fraction was collected. After removing
the magnetic field, CD11b-positive cells were eluted as a positive
fraction. Additionally, cells were stained with CD11b-PE and
CD45 PerCP-Cy5.5 antibodies (BD Pharmingen). IL-10 expres-
sion on microglia/macrophages was determined by a staining of
CD11b
+ cells with Alexa Fluor 647 labelled IL-10 antibody (1:20,
Biolegend). Propidium iodide (PI, Sigma) was added (1 mg/ml) to
exclude debris and dead cells from analysis. All live CD11b-
positive cells were assessed by flow cytometry (FACSCalibur).
Data were acquired and analyzed using CellQuest software.
RNA isolation and quantification of gene expression
Total RNA from sorted CD11b
+ cells was isolated with RNeasy
Mini Kit (Qiagen, Hilden, Germany). The quality and yield of
RNAs were verified using the 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). First-strand cDNA was synthe-
sized from 1 mg of total RNA (DNase-treated) in a 20 ml reverse
transcriptase reaction mixture. TaqMan Express Plates (Applied
Biosystems) with specific primers and FAM labelled probe sets
were employed for determination of arg-1, ccl7, chi3l1, chi3l3 (ym1),
c-myc, cox-2, cx3cr1, cxcl14, fizz1 (retnla), hif-1a, ifn-b1, il-10, il-12a,
il-17a, il-1b, inos, irf-7, kcnk10, mt1-mmp, mmp2, mmp9, smad6, smad7,
socs2, stat1, stat3, tgf-b1 and tnfsf10 expression; 18s rRNA was used
as an internal reference gene. The thermal cycling conditions
were: 10 min at 95uC and 40 cycles of 95uC for 15 sec and 1 min
at 60uC for annealing and extension. The expression of m-csf and
gm-csf in GL261 glioma cells and primary astrocytes was evaluated
using quantitative real-time PCR. Reaction volume (20 ml)
consisted of cDNA equivalent to 50 ng RNA, 16 SYBR Green
PCR master mix (Applied Biosystems) and 0.9 mM of each primer.
The thermal cycling conditions were as follows: 50uC for 2 min,
95uC for 10 min, followed by 40 cycles of 15 s at 95uC for
denaturation and 1 min. at 60uC for annealing and extension.
Relative quantification of gene expression was determined using
the comparative CT method.
Measurement of arginase activity
Arginase activity was determined in brain tissue extracts using a
colorimetric method based on the conversion of L-arginine to L-
ornithine as described [26]. Optical density of ornithine-ninhydrin
complexes formed in the samples was measured using a microplate
reader at 515 nm. Arginase activity was expressed as U/mg
protein (1 Unit=1 mmol of L-arginine to ornithine per minute at
pH 9.5 and 37uC).
Evaluation of MMP-2 activity by gelatin zymography and
fluorescent assay
Tissue extracts (70 mg protein) were resolved by SDS-PAGE on
8% gel containing 2 mg/ml of gelatin (Sigma), 380 mM TRIS-
HCl (pH 8.8), 0.1% SDS, 0.1% ammonium persulfate and 0.6 ml/
ml of TEMED (tetramethylethylenediamine, Sigma). After
electrophoresis, the gel was rinsed twice in 2.5% Triton X-100
at room temperature and renaturated in a buffer containing
50 mM Tris-HCl pH 7.6, 10 mM CaCl2,1 mM ZnCl2,1 %
Triton X-100 and 0.02% sodium azide (at 37uC, 100 rpm). After
72 hours the gel was stained with Coomasie brilliant blue. MMP-2
activity in tissue extracts was quantified by measuring the
fluorescence released by cleavage of DQ-gelatin (Invitrogen).
The extracts were incubated with 100 mg/ml of FITC-gelatin in
0.5 M Tris-HCl, 1.5 M NaCl, 50 mM CaCl2, 2 mM sodium
azide, pH 7.6, for 24 hours at 37uC. Fluorescence intensity was
measured in a microplate reader (excitation 485 nm, emission
530 nm).
Statistical analysis
The results were expressed as means 6 standard error of the
mean (SEM). Statistical analyses were performed using a Statistica
software (ver. 7.1 StatSoft. Inc, OK, USA). Statistical significance
was determined by U-Mann-Whitney and ANOVA tests.
Results
Activated microglia and blood derived macrophages
accumulate in the tumor
GL261-glioma cells strongly attract Iba1-positive microglia/
macrophages and cause their morphological transformation
(Fig. 1A). Only a few ramified Iba1-positive cells were detected
in the intact brain. Numerous amoeboid, Iba1-positive cells
accumulated within and around the implanted glioma cells, while
ramified microglia, with thin branching processes and a small cell
body were detected in the tumor-free parenchyma (Fig. 1A).
Interestingly, the cells in the close vicinity of tumor were evidently
more activated and amoeboid than the cells located distantly.
Microglia specific staining was mostly localized in the ipsilateral
hemisphere (Fig. 1B).
Differences in the surface expression of CD11b and CD45
antigens on microglia (CD11b
+/CD45
low) and blood-derived
macrophages (CD11b
+/CD45
high) isolated from tumor tissue
permitted distinction of the two populations by flow cytometry
[27]. We determined the relative contribution of resident and
blood-derived cells to the Iba1-positive population within the
tumor. Since microglia/macrophages are the major CD11b-
expressing cell population in the brain, a magnetic-bead-
conjugated anti-CD11b antibody was used to separate these cells
from tumor-bearing hemispheres. Propidium iodide was added to
the samples to exclude debris and dead cells. All live CD11b/
CD45-positive cells were acquired and analyzed using CellQuest
software (Fig. 1C). Quadrant gates were drawn on the negative
fraction containing mostly CD45
2/CD11b
2 cells (Fig. 1D) and
detection of only few CD11b
+/CD45
+ cells, confirmed a sensitive
separation. Microglia and macrophages (Fig. 1E) were identified
according to their specific surface antigen expression profile as
CD11b
+/CD45
low and CD11b
+/CD45
high populations, respec-
tively. In naı ¨ve, microglia constituted the prevalent population
(93%) of CD11b
+ cells in the brain and the number of microglia/
macrophages did not change in sham-operated animals injected
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23902Figure 1. Accumulation and activation of microglia/macrophages in experimental glioma. A. Representative confocal images of brain
sections 15 days after implantation of pEGFP-N1 GL261 cells into the striatum of C57BL/6 mice. Note the infiltration and morphological
transformation of glioma-infiltrating Iba1
+ cells. Scale bar: left image – 1000 mm, right image – 20 mm. B. Contralateral and ipsilateral hemisphere from
tumor-bearing brain 15 days after injection of pEGFP-N1 GL261 cells. Images showed merged Iba1 and EGFP fluorescence. Scale bar=750 mm. C.
Microglia/macrophages were separated using a magnetic-bead-conjugated anti-CD11b antibody and stained with CD45 PerCP-Cy5.5 and CD11b PE
prior to FACS acquisition. Propidium iodide staining was performed to eliminate necrotic/apoptotic cells (Gate R3, R4) and viable cells were gated
(Gate R1; B1, Gate R2; B2). D. Efficiency of CD11b-positive cells separation in the negative fraction (CD11b-negative cells) from each sample was
controlled. E. Representative dot plots for microglia (Gate R4, CD11b
+/CD45
low) and macrophages (Gate R5, CD11b
+/CD45
high) from tumor-bearing
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significantly from the 8th day, while the number of macrophages
increased at the 15th day after tumor implantation (Fig. 1F).
CsA effectively impairs the pro-invasive activity of microglia in
vitro and in organotypic brain slices [22]. As kinetic studies
indicated different phases of microglia and macrophage accumu-
lation, CsA was injected starting from the 2nd or 8th day after
tumor implantation. Systemic treatment with CsA (2 and 10 mg/
kg), reduced the abundance of Iba1-positive cells (Fig. 2A). These
cells were only moderately enlarged and less activated in CsA-
treated mice as compared to PBS-treated mice. Quantification of
tumor-infiltrating microglia/macrophages revealed a ,2.6-fold
increase in the number of microglia and a ,30-fold increase in the
number of macrophages 15 days after tumor implantation. Early
treatment with 10 mg/kg CsA reduced the number of infiltrating
microglia by 27%, while postponed administration of CsA strongly
reduced infiltration of both microglia (by ,47%) and macro-
phages (by 71%) (Fig. 2B–C). Immunofluorescence studies and
quantification of glioma-infiltrating CD11b
+ cells clearly demon-
strate inhibition of accumulation of these cells by CsA in
experimental gliomas.
Detection of DNA fragmentation in situ by TUNEL staining
o nb r a i ns l i c e sr e v e a l e da ni n c r e a s ei nt h en u m b e ro fa p o p t o t i c
cells after CsA treatment (Fig. 3A). Confocal microscopy
analysis showed that most of the TUNEL-positive cells (in red)
in CsA-treated animals did not co-localize with the implanted
tumor cells (in green) (Fig. 3B). Staining with antibodies against
GFAP (glial fibrillary acidic protein, a marker for astrocytes) and
NSE (neuronal specific enolase, a marker for neurons) showed
no co-localization of neuronal/astroglial markers with TUNEL
Figure 2. Influx of microglia/macrophages into the tumor is blocked by CsA. A. Representative confocal images of Iba1 staining in intact
brain tissue, tumor-bearing brain slices from mice treated with PBS or CsA. Scale bar=20 mm. B–C. Quantification of microglia and blood-derived
macrophages in naı ¨ve, tumor-bearing and CsA-treated mice (4 per group). Each bar represents the mean 6 SEM.
***p,0.001,
**p,0.01 tumor-bearing
versus naı ¨ve mice;
##p,0.01, CsA-treated versus PBS-treated tumor-bearing mice.
doi:10.1371/journal.pone.0023902.g002
hemispheres. F. Kinetics of microglia/macrophage influx into tumor tissue. CD11b
+ cells separated from the brains of naı ¨ve, sham operated and
tumor-bearing mice at day 3, 8 or 15 after implantation (n=4/group) were sorted according to CD45 expression. Each bar represents the mean 6
SEM;
***p,0.001,
*p,0.05 tumor-bearing mice at 8th day versus naı ¨ve mice;
##p,0.01 tumor-bearing mice at day 15 versus day 8.
doi:10.1371/journal.pone.0023902.g001
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(in red) co-localized with Iba-1 staining (in blue) (Fig. 3C), that is
consistent with the induction of cell death mostly among glioma-
infiltrating activated microglia/macrophages in CsA-treated
mice. Quantification of Iba1
+/TUNEL
+ cells among TUNEL-
positive cells inside the tumor revealed an increase in the
number of double-positive cells after delayed CsA treatment
(Fig. 3D).
Figure 3. CsA induces cell death within tumor-associated microglia/macrophages. A. Quantification of the number of TUNEL-positive cells
per 1 mm2 of tumor area in saline and CsA-treated mice was counted using Image Pro-Plus software. The results show the median of 5–6 mice in
each group. A statistical significance was determined by U-Mann-Whitney test; **p,0.01. B. Detection of DNA fragmentation in situ in EGFP-N1 GL261
tumour bearing brain section visualised with TUNEL staining (red fluorescence) by confocal microscopy. Scale bar=20 mm. C. Identification of TUNEL-
positive cells (red) in tumour-bearing slices. Sections were subjected to TUNEL reaction and stained for Iba1 (microglia/macrophages). Images were
acquired using confocal microscopy and Z-stack projection was performed. Representative Z-stack images (1–4) of saline- and CsA-treated mice
(10 mg/kg, postponed treatment) demonstrate a co-localization of TUNEL-positive cells (red) and Iba1-positive cells (blue). Scale bar=20 mm. D.
Quantification of Iba+/TUNEL+ cells among TUNEL-positive cells. The results show the mean 6 SD (4–6 mice per group); **p,0.01 significant change
between postponed (10 mg/kg) and early treated mice (10 mg/kg).
doi:10.1371/journal.pone.0023902.g003
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produce pro-inflammatory cytokines
To understand the functional relevance of glioma infiltration
by immune cells, we determined the levels of pro- and anti-
inflammatory cytokines in whole brain tissue extracts using a
multiplex 10 Th1/Th2 cytokine assay. An intracerebral LPS
injection up-regulated TNFa and IL-6 levels, but reduced IL-10,
IL-17 and GM-CSF levels. In tumor-bearing mice only IL-10 and
GM-CSF levels were significantly elevated when compared to
naı ¨ve mice (Fig. 4A). Interestingly, CsA treatment strongly
reduced IL-10 and GM-CSF production, with the postponed
treatment being the most effective (Fig. 4B). Flow cytometric
analysis of magnetically sorted cells revealed that the IL-10
protein is expressed mostly in CD11b
+/CD45
high macrophages
(Fig. 4C). The level of gm-csf expression, but not m-csf,w a s
significantly higher in GL261 glioma cells than in non-
transformed murine astrocytes (Fig. 4D). Treatment with 0.1
and 1 mM CsA (doses corresponding to in vivo blood concentra-
tions) leads to downregulation of gm-csf mRNA level in GL261
glioma cells (Fig. 4E).
Gene expression in glioma-infiltrating microglia/
macrophages
We analysed the expression of 28 genes, putatively character-
izing the M1- or M2-type of macrophages (Table 1), in
magnetically sorted CD11b
+ cells from naı ¨ve and tumor-bearing
mice. The expression of five genes: arg-1, cxcl14, ifn-b1, cox-2, mt1-
mmp significantly differed in CD11b
+ cells from tumor comparing
to naı ¨ve mice. Up-regulation of arg-1, cxcl14, mt1-mmp and cox-2
expression and down-regulation ifn-b1 in tumor CD11b
+ cells was
observed (Fig. 5A). Early treatment with CsA decreased ifn-b1,
cxcl14 and mt1-mmp expression (p,0.05) in tumor CD11b
+ cells
compared to controls, and delayed CsA administration decreased
arg-1 and cxcl14 expression. Up-regulated expression of cox-2 in
CD11b
+ cells from gliomas remained unaffected by CsA.
However, the expression of il-1b was up-regulated in CD11b
+
Figure 4. Cytokine profile in glioma-bearing brains. A. The levels of ten pro/anti-inflammatory cytokines were determined by flow cytometry
in protein extracts isolated from hemispheres of naı ¨ve, LPS-injected and tumor-bearing mice. The results show the means 6 SEM (n=5 per group);
#p,0.05 significant change between LPS-treated v. naı ¨ve mice;
*p,0.05 significant difference between tumor-bearing v. naı ¨ve mice. B. Elevated
levels of IL-10 and GM-CSF detected in tumors are reduced by CsA treatment. Each dot represents an individual animal; a horizontal line represents a
mean of each group;
*p,0.05;
**p,0.01. C. Expression of IL-10 in glioma-infiltrating microglia and macrophages. Left panel: expression of IL-10 on
sorted CD11b
+ cells (50,000 cells) determined by flow cytometry with the anti-IL-10 antibody conjugated to Alexa Fluor647. Representative
histograms of IL-10 detection in microglia (light grey) and macrophages (dark grey) cells from naı ¨ve (a) and tumor-bearing (b) brains. Right panel:
quantification of microglia/macrophages expressing IL-10 in naı ¨ve and tumor-bearing brains (means 6 SEM, 3 animals per group); significant increase
of IL-10-positive microglia (** p,0.01) and macrophages (
### p,0.001) in tumor-bearing brains. D. Quantification of gm-csf and m-csf expression in
GL261 glioma cells and non-transformed astrocytes (means 6 SD from 3 experiments). E. Quantitative evaluation of gm-csf mRNA expression in
GL261 glioma cells exposed to 0.1 and 1 mM CsA for 24 hours (means 6 SD from two experiments with three or four replicates per condition)
compared to untreated control cells. Statistical analysis was done by Student t test, ** p,0.01.
doi:10.1371/journal.pone.0023902.g004
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fold increase in the il-1b mRNA level in CD11b
+ cells from LPS-
injected brains (not shown).
We assessed total gelatinase activity in the tumor extracts using
gelatin zymography. Only MMP-2 activity was clearly detected in
extracts from tumor-bearing brains, and it was higher than in
extracts from tumor-free brains (Fig. 5C). Changes in MMP-2
activity were confirmed using a fluorescein-conjugated DQ gelatin
assay. Following CsA treatment, MMP-2 gelatinolytic activity was
significantly reduced by CsA treatment, particularly after early
treatment CsA (Fig. 5D). The level of arg-1 mRNA was elevated in
tumor-derived CD11b
+ cells, thus we measured arginase activity in
brain extracts. Figure 5B shows increased arginase activity in
extracts from tumor-bearing brains in comparison to tumor-free
tissue. Only the delayed treatment diminished significantly
arginase activity.
CsA treatment strongly impairs the growth of intracranial
gliomas
As accumulation of tumor-associated CD11b
+ cells with some
features of the M2 phenotype was reduced by CsA treatment, we
determined if CsA and FK506 (similarly acting drug, more
effectively crossing the blood brain barrier) would affect tumor
growth. Drugs were injected i.p., every two day starting from the
2nd day or every day from the 8th day after glioma inoculation
(Fig. 6A). CsA treatment strongly reduced tumor growth in vivo
(Fig. 6B). Quantification of tumor volumes in CsA- and FK506-
treated mice showed significantly smaller tumors when compared
to control mice. After early treatment with either 2 or 10 mg/kg
CsA, tumor volume was reduced by 59% (1.1560.36 mm
3) and
,78% (0.6360.24 mm
3), respectively, versus an average tumor
volume of 2.8360.23 mm
3 in control mice. In FK506-treated
mice, tumor reduction reached ,69% (0.8860.48 mm
3) (Fig. 6C).
When the treatment was postponed to the 8th day, only the higher
dose of CsA (10 mg/kg) was effective in reducing tumor volume by
,73% (0.7660.16 mm
3). FK506 treatment diminished tumor
volume by ,52% (1.3560.20 mm
3) (Fig. 6D).
Discussion
The concept that macrophages play instructive roles in tumor
growth by regulating cell motility, invasion, angiogenesis and
immunomodulation has gained great attention over last years.
[2,28,29]. Tumor-derived cytokines such as IL-4, IL-10, TGF-b,
and M-CSF are believed to polarise tumor-infiltrating macro-
phages towards an M2 anti-inflammatory phenotype [30,31].
Mechanisms of accumulation and a role of microglia/macrophag-
es in glioma pathobiology are still poorly understood and
controversial. Several experimental studies demonstrated that
microglia contribute to glioma progression by secreting growth
factors, angiogenic molecules, extracellular matrix–degrading
enzymes, and immunosuppressive factors [21,22,23,24]. However,
Galarneau et al. showed that ablation of CD11b cells (ganciclovir-
treated B6 mice expressing a mutant form of HSV-1 TK
mt-30
under CD11b promoter) increases glioma growth [32], a recent
study demonstrated that ablation of CD11b in vivo (ganciclovir-
treated CD11b-HSVTK mice) decreases tumor size and improves
survival [33].
We demonstrated that Iba1-positive cells infiltrate implanted
GL261 gliomas and close distance interactions result in amoeboid
transformation of these cells. Our analysis of sorted CD11b
+ cells
followed by CD11b/CD45 staining shows the increase in a
number of microglia (CD11b
+/CD45
low) and a surprisingly high
infiltration of tumor tissue by blood-derived macrophages
(CD11b
+/CD45
high). Kinetics of changes in the number of
microglia and macrophages infiltrating gliomas showed early
accumulation of microglia in the first week, followed by
accumulation of macrophages afterwards.
Amongst ten analyzed pro/anti-inflammatory cytokines, only
IL-10 and GM-CSF levels were elevated in the tumor-bearing
brains comparing to naı ¨ve mice. Flow cytometry analysis of
magnetically-sorted CD11b
+ cells demonstrates that IL-10 is
produced mostly by infiltrating macrophages. The expression of
gm-csf was 5 times higher in GL261 glioma cells than in cultured
murine astrocytes; therefore, these cells are likely a source of newly
synthesized cytokine. The relevance of this finding for human
pathology is unclear, because although human astrocytoma and
glioblastoma cell lines produce GM-CSF, no evidence of its
production by glioblastoma cells was found in vivo [34]. Our
findings suggest that GM-CSF and IL-10 could be important
Table 1. Quantification of selected M1/M2 phenotype-
associated gene expression in CD11b
+ cells isolated from
naı ¨ve and tumor-bearing mice.
Genes CD11b
+ cells from glioma
Fold change p-value
arg-1 3734.42 7.00E-04
ccl7 0.72 0.3951
chi3l1 1.31 0.7441
chi3l3 (ym1) 7.24 0.0586
c-myc 0.27 0.0478
cx3cr1 0.14 0.0643
cxcl14 3.21 0.0016
hif-1a 1.57 0.4294
ifn-b1 0.24 0.0137
il-10 0.75 0.6344
il-12a 14.83 NA
il-17a 8.24 NA
il1-b 11.09 1.00E-04
irf-7 30.11 9.00E-04
kcnk10 4.63 NA
mmp-9 0.78 0.337
mt1-mmp 3.21 0.0099
mmp-2 0.56 0.699
inos 88.82 0.085
cox-2 9.57 0.018
fizz1 (retnla) 0.36 0.0731
smad-6 1.25 0.6346
smad-7 0.26 0.2283
socs-2 5.89 0.0671
stat-1 10.38 2.00E-05
stat-3 0.9 0.5458
tgf-b1 0.68 0.1778
tnfsf10 2.11 0.2265
Gene expression was analyzed by real-time PCR and the results are presented as
fold changes of CD11b
+ cells isolated from tumor brains versus those from
naı ¨ve brain tissue. Numbers corresponding to the significantly changed genes
(t-test generated p-value,0.05) are marked in bold; NA - not available.
doi:10.1371/journal.pone.0023902.t001
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infiltrating microglia/macrophages.
The present study shows for the first time the expression of
putative markers of the M2 phenotype in CD11b
+ cells infiltrating
gliomas. Out of many markers, Arginase 1 is the most consistent.
Arginase 1 catalases arginine hydrolysis to urea and ornithine, and
competes for its substrate with inducible nitric oxide synthase
(iNOS) in IFN-c-stimulated macrophages. The macrophagic
expression of Arg-1 is tightly regulated by exogenous stimuli such
as IL-4 and IL-13 [35]. L-arginine depletion due to extensive
myeloid arginase activity may suppress T cell immune responses
[36]. Expression of iNos and Arg-1 define classically and
alternatively activated macrophages in the context of Th2-
polarised immune responses [37,38]. Enhanced expression of
Arg-1 associated with TAMs was found in 3LL murine lung
carcinoma [39], in the human papillomavirus E6/E7-expressing
murine tumors [40] and in CD11b
+/CD14
2 myeloid cells from
renal carcinoma patients [41]. Cyclooxygenase-2 (COX-2)
expression and prostaglandins (PGE) have been implicated in
the development of many cancers [42] serving as pro-inflamma-
tory mediators under some conditions, but having anti-inflamma-
tory and immunosuppressive properties under other conditions
[43]. Stimulation of PGE2 signalling in dendritic cells facilitates
their migration and maturation, while in T cells potently
suppresses activation and proliferation [44]. The observed up-
regulation of cox2 mRNA in CD11b
+ cells corroborates with a
study showing the macrophagic expression of COX-2 and
enhanced production of PGE1 by glioma-derived factors [45]. A
chemokine CXCL14 was identified as a chemoattractant for
monocytes [46], and can induce dendritic cell migration and
maturation [47,48]. The enhanced expression of cxcl14 in glioma-
infiltrating CD11b
+ cells could be involved in macrophage
infiltration or their differentiation. Down-regulation of cxcl14
expression in CsA-treated mice correlates with reduced CD11b
+
cell accumulation.
The development of a tumor vasculature is a crucial step for the
survival and metastasis of malignant tumors. Accumulation of
tumor-associated macrophages correlates with the formation of a
blood vessel network and the transition to malignancy in the
MMTV-PyMT experimental breast cancer in mice. Depleting
macrophages in tumors in CSF-1 null mice (Csf1
op) delayed the
angiogenic switch and malignant transition, whereas restoration of
Figure 5. Alterations of gene expression in infiltrating microglia/macrophages and intracranial gliomas are modulated by CsA. A.
Gene expression in magnetically sorted CD11b
+ cells from tumor-bearing and naı ¨ve brains was determined by qPCR. Expression of five genes was
significantly altered in CD11b
+ cells: arg-1 (p=0.000003); cxcl14 (p=0.0001); ifn-b1 (p=0.0002); cox-2 (p=0.000002); mt1-mmp (p=0.00002);n = 5
animals per group;
*p,0.05,
**p,0.01. The middle line represents the median value. Lower DCT are consistent with higher gene expression. B.
Quantification of arginase activity in brain tissue extracts from naı ¨ve and tumor-bearing mice treated either with PBS or CsA. Results represent the
mean 6 SEM of 4–5 mice;
*p,0.05, tumor-bearing versus tumor-free hemispheres;
#p,0.05, CsA (10 mg/kg, 8th) versus PBS-treated, tumor-bearing
mice. C. MMP-2 activity in proteins extracts from the brains of naı ¨ve (N1–5) and tumor-bearing mice (T1–5) determined by gel zymography. Active
MMP-2 detected as a prominent band at 62 kDa. D. Quantification of MMP-2 activity using the cleavage of fluorescent DQ-gelatin substrate; means 6
SEM of 4–6 mice;
**p,0.01, tumor-bearing versus naı ¨ve brain extracts;
###p,0.001,
#p,0.05, CsA- versus PBS-treated tumor-bearing mice.
doi:10.1371/journal.pone.0023902.g005
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High-grade gliomas demonstrate the highest levels of tumor
angiogenesis when compared to non-neural solid cancers.
Numbers of infiltrating macrophages have been found to correlate
with small vessel density and tumor grade [49]. We observed an
increase in microglia/macrophage infiltration and the develop-
ment of a dense vessel network in implanted gliomas (not shown).
Furthermore, early treatment with CsA inhibited vessel network
development in tumor-bearing mice. Evaluation of implanted
GL261 mouse gliomas by MR microimaging indicated blood-
brain barrier disruption already in early-stage of tumors (1–2
week) [50]. Thus intraperitoneally administered CsA can easily
penetrate brain parenchyma.
Systemic delivery of CsA at doses of 2 or 10 mg/kg significantly
attenuate tumor growth in C57BL/6 mice; weaker effects were
observed after the treatment with FK506. Tumor volumes were
decreased even when the CsA injection was postponed until the
8th day after glioma implantation. High expression of Arg-1 and
IL-10 with low expression of inflammatory cytokines suggested
differentiation of CD11b
+ cells into the M2 phenotype. The
reduction of cxcl14 expression in CD11b
+ cells, decrease of GM-
CSF and IL-10 levels in CsA-treated mice suggest that CsA down-
regulates the production of factors crucial for accumulation and
alternative activation of microglia/macrophages. Moreover, CsA
treatment resulted in the reduced expression of mt1-mmp in glioma-
infiltrating CD11b
+ and overall down-regulation of the MMP-2
Figure 6. Reduction of tumor growth in CsA-treated animals. A. Scheme of experiment. B. Representative images of EGFP-GL261 tumors in
mice treated with PBS or 10 mg/kg CsA, 2nd; scale bar=1 mm. C–D. Quantification of tumor volumes in PBS, CsA-treated or FK506-treated mice after
early (C) or postponed (D) treatment. Results for individual animals are presented; the bold line represents the median of 5–10 mice in each group.
**p,0.01,
***p,0.001, tumor volumes in drug-treated versus control mice.
doi:10.1371/journal.pone.0023902.g006
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derived MT1-MMP in regulation of MMP-2 activity [21,23].
Altogether, we demonstrate that resident microglia and blood-
derived macrophages contribute to a pool of glioma-infiltrating
immune cells, regulate tumor angiogenesis and invasion, which are
essential for glioma progression. Induction of cell death in tumor-
infiltrating microglia/macrophages considerably reduced a pool of
TAM and might cause an attenuation of tumor growth. Postponed
treatment with CsA seems to be more effective than early
treatment because it affects already accumulated microglial cells
and delays attraction of blood-derived macrophages. Despite of
developments of new therapeutics, glioblastomas are difficult to
treat due to frequent dysfunctions of tumor suppressors and
oncogenes; the mean survival of patients with glioblastomas ranges
between 1–2 years [51,52]. Counteracting of brain macrophage
accumulation and activation should be taken into account when
considering the development of more effective therapy against
malignant gliomas.
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